Our research demonstrated that JQ1 could suppress glioma cell's migration and invasion ability via downregulation of the Akt pathway, indicating that this adjuvant treatment could not only improve JQ1 efficiency but also overcome its limitation. This evidence concerns the gene AKT1 and glioma.